Loading
Immunologist who showed that the gut microbiome shapes responses to immunotherapy and chemotherapy.
Laurence Zitvogel is Research Director of INSERM U1015 at Gustave Roussy. An immunologist, her specialisms are tumour immunology, the gut microbiome and immunotherapy, and immunogenic cell death. With Guido Kroemer she co-discovered immunogenic cell death, and she led the studies linking gut microbiota composition to the response to immune checkpoint inhibitors. Her Science paper showed that the gut microbiome influences the efficacy of PD-1-based immunotherapy against epithelial tumours. This work opened the field of microbiome-directed cancer therapy, and her publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors | Science | 2018 |
Shares Protect the gut flora of patients about to start immunotherapy, Test a high-fibre diet as an immunotherapy adjunct, Dietary fibre and the gut microbiome for immunotherapy response, Immune checkpoint inhibitors.
Shares Take faecal transplant plus immunotherapy to a definitive trial, Faecal microbiota transplantation for PD-1 non-responders, Immune checkpoint inhibitors.
Shares Take faecal transplant plus immunotherapy to a definitive trial, Faecal microbiota transplantation for PD-1 non-responders, Immune checkpoint inhibitors.
Shares Protect the gut flora of patients about to start immunotherapy, Dietary fibre and the gut microbiome for immunotherapy response, Immune checkpoint inhibitors.
Shares Faecal microbiota transplantation for PD-1 non-responders, Dietary fibre and the gut microbiome for immunotherapy response, Immune checkpoint inhibitors.
Shares Immunogenic cell death, Immune checkpoint inhibitors.